Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).

Aditya BardiaSara A HurvitzAngela M DeMicheleAmy S ClarkAmelia ZelnakDenise A YardleyMeghan KaruturiTara SanftSibel BlauLowell HartCynthia MaHope S RugoDas PurkayasthaStacy Moulder

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Preliminary TRINITI-1 safety and efficacy results support further investigation of CDK4/6 blockade and targeting of the PI3K/AKT/mTOR signaling pathway in patients with ET-refractory HR+/HER2- ABC after progression on a CDK4/6i.

Keyphrases

cell cycle
signaling pathway
study protocol
clinical trial
cell proliferation
epithelial mesenchymal transition
phase iii
cancer therapy
induced apoptosis
drug delivery